norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis

Peter Fickert, Gideon M. Hirschfield, Gerald Denk, Hanns-ulrich Marschall, Istvan Altorjay, Martti Färkkilä, Christoph Schramm, Ulrich Spengler, Roger Chapman, Annika Bergquist, Erik Schrumpf, Frederik Nevens, Palak Trivedi, Florian P. Reiter, Istvan Tornai, Emina Halilbasic, Roland Greinwald, Markus Pröls, Michael P. Manns, Michael Trauner

Research output: Contribution to journalArticlepeer-review

97 Citations (Scopus)
190 Downloads (Pure)

Abstract

Background & Aim Primary sclerosing cholangitis (PSC) represents a devastating bile duct disease, currently lacking effective medical therapy. 24-norursodeoxycholic acid (norUDCA) is a side chain-shortened C23 homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory and anti-fibrotic properties in a preclinical PSC mouse model. A randomized controlled trial, including 38 centers from 12 European countries, evaluated the safety and efficacy of three doses of oral norUDCA (500 mg/d, 1,000 mg/d or 1,500 mg/d) compared with placebo in patients with PSC. Methods One hundred sixty-one PSC patients without concomitant UDCA therapy and with elevated serum alkaline phosphatase (ALP) levels were randomized for a 12-week treatment followed by a 4-week follow-up. The primary efficacy endpoint was the mean relative change in ALP levels between baseline and end of treatment visit. Results norUDCA reduced ALP levels by −12.3%, −17.3%, and −26.0% in the 500, 1,000, and 1,500 mg/d groups (p = 0.029, p = 0.003, and p <0.0001 when compared to placebo), respectively, while a +1.2% increase was observed in the placebo group. Similar dose-dependent results were found for secondary endpoints, such as ALT, AST, γ-GT, or the rate of patients achieving ALP levels <1.5× ULN. Serious adverse events occurred in seven patients in the 500 mg/d, five patients in the 1,000 mg/d, two patients in the 1500 mg/d group, and three in the placebo group. There was no difference in reported pruritus between treatment and placebo groups. Conclusions norUDCA significantly reduced ALP values dose-dependently in all treatment arms. The safety profile of norUDCA was excellent and comparable to placebo. Consequently, these results justify a phase III trial of norUDCA in PSC patients.
Original languageEnglish
JournalJournal of Hepatology
Early online date18 May 2017
DOIs
Publication statusE-pub ahead of print - 18 May 2017

Keywords

  • Alkaline phosphatase
  • Bile acid treatment
  • Cholestasis
  • Sclerosing cholangitis
  • Side chain-shortened bile acids
  • Cholehepatic shunting
  • Ursodeoxycholic acid

Fingerprint

Dive into the research topics of 'norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis'. Together they form a unique fingerprint.

Cite this